Helmy Eltoukhy is a co-founder of Guardant Health and has served as Chief Executive Officer and a member of the Board since January 2013. On August 5, 2021, he was appointed Chairperson of the Board and Co-CEO.
Prior to co-founding Guardant Health, Dr. Eltoukhy held various positions at Illumina, Inc. from August 2008 to December 2012, including Senior Director of Advanced Technology Research, where he developed novel chemistries, hardware and informatics for genetic analysis systems. In June 2007, he co-founded Avantome Inc. to commercialize semiconductor sequencing and served as its Chief Executive Officer until its acquisition by Illumina in August 2008.
He joined the Stanford Genome Technology Center as a post-doctoral fellow in 2006 to work on low-cost DNA sequencing technologies. During his doctoral studies and at the Stanford Genome Technology Center, he developed the first semiconductor sequencing platform and first base-calling algorithm for next-generation sequencing under several National Human Genome Research Institute grants. He received his Ph.D., M.S. and B.S. degrees in electrical engineering from Stanford University.